TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$16.55 USD
-0.21 (-1.25%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $16.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Brokerage Reports
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 121 - 140 ( 277 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: TG Therapeutics, Inc.
Industry: Medical - Products
GENUINE Win Bodes Well for Accelerated Approval; Reit Buy and $18 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TG Therapeutics, Inc.
Industry: Medical - Products
We are transferring coverage to Mark Breidenbach, Ph.D., due to the departure of the covering analyst and placing shares Under Review.
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
But Wait, There''s More; Just In Case ''1202 Needed More Convincing
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Healthcare - Innovations in Oncology Corporate Access Day Recap
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q16 Results; Expect Nice Update at ASH as Thesis Continues to Strengthen
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Now That''s MOA Data; New Views Into TGR-1202 Differentiation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Starting a Combo Study to Go Full Force After c-Myc; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Making The Hard/Right Decision for GENUINE; No Issue Here
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q Update: Mixed News from CLL Throw the Spotlight on MS
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: TG Therapeutics, Inc.
Industry: Medical - Products
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.